What Emerade treats: main uses and benefits

Emerade is an adrenaline (epinephrine) auto-injector that is relevant when supportive symptom management is appropriate for severe symptoms associated with acute allergic reactions. The primary use is considered relevant for the emergency treatment of severe acute allergic reactions (anaphylaxis). This treatment is commonly used across conditions presenting with acute episodes triggered by common allergens such as foods, insect stings, and medicines, or in cases of exercise-induced or idiopathic anaphylaxis.

The medication's active ingredient, adrenaline, supports the patient during difficult episodes by helping to counteract the severe physiological strain. The drug plays a role in managing symptoms related to heightened physiological activity and helps address symptoms that interfere with daily functioning, such as symptoms related to physical discomfort and symptoms related to systemic imbalance. This assists with maintaining functional stability and contributes to easing the overall symptom load. The auto-injector is commonly used in settings where short-term symptom stabilization is important until further medical care is available.

“The auto-injector may assist with maintaining a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for symptoms related to systemic imbalance

Regulatory References

1. Health Canada Prescribing Information for Emerade

Who Can and Cannot Use Emerade?

Emerade (epinephrine/adrenaline) is an emergency, life-saving medication, and its eligibility profile reflects this critical use, as documented in regulatory information.

Eligibility Scope

Category	Official Regulatory Statement
Contraindications	None. There are no absolute contraindications to the use of Emerade in a life-threatening allergic emergency.
Use Not Recommended	Children below 15 kg bodyweight; this restriction is based on the inability to administer the required lower dose with sufficient accuracy with the available auto-injector.

---

Population and Condition-Specific Rules

Eligibility is primarily determined by bodyweight and the severity of the emergency. Dosage must be based on bodyweight, not age alone. Children weighing 15 kg to 30 kg are eligible for the 150 microgram dose.

Use with caution is specified for certain underlying health conditions, as these patients may have an increased risk for adverse reactions after administration. Conditions requiring caution include pre-existing heart diseases, hypertension, hyperthyroidism, diabetes, and severe renal impairment.

For pregnancy, use is permitted only when the potential benefit to the mother outweighs the possible risk to the fetus, an assessment driven by the emergency context. Breastfeeding is permitted after the use of Emerade.

Interactions with other medicines and products

The official regulatory profile for adrenaline (epinephrine) auto-injectors addresses potential interactions strictly based on the modification of the drug’s intended effects. Due to its life-saving purpose in a severe allergic emergency, the official label specifies there are no absolute contraindications to the use of Emerade.

Pharmacodynamic Effect Modification

Certain medicinal products are documented to interact with adrenaline, resulting in either a heightened or a reduced response. Co-administration with agents such as Tricyclic Antidepressants, MAO Inhibitors, and COMT Inhibitors may potentiate the effects of adrenaline, which could increase the pressor response. Conversely, the therapeutic actions may be antagonized by substances such as Beta-Adrenergic Blocking Drugs and Alpha-Adrenergic Blocking Drugs, which may counteract the drug's cardiovascular or vasoconstricting actions.

Specific Risk and Metabolic Notes

Regulatory documents highlight interactions that increase specific risks. Agents such as Cardiac Glycosides, Quinidine, and Halogenated Hydrocarbon Anesthetics are documented to increase the arrhythmogenic potential, necessitating careful observation. Furthermore, adrenaline potentiates the hypokalemic effects of co-administered potassium-depleting drugs. The drug's metabolic consequence of increasing blood glucose levels is also noted as a specific consideration for patients on insulin or oral hypoglycaemic treatment.

Sympathetic Agonism and Vascular Tone Restoration

The mechanism of Emerade (Adrenaline/Epinephrine) is defined by its non-selective agonism across the sympathetic nervous system's adrenergic receptors, operating simultaneously on cardiovascular, respiratory, and immune pathways. This domain covers the binding of adrenaline to Alpha-1 (α1) receptors on peripheral blood vessels and Beta-1 (α1) receptors in the heart. The alpha1 agonism triggers significant vasoconstriction, directly opposing pathological vasodilation. Concurrently, beta1 agonism enhances the heart's force and rate, increasing cardiac output. The combined action increases systemic blood pressure and supports the maintenance of vital organ perfusion.

Airway Relaxation and Mediator Suppression

This domain focuses on adrenaline’s action at Beta-2 (β2) adrenergic receptors, primarily located in the airways and on immune cells. beta2 agonism leads to the relaxation of bronchial smooth muscle, which reduces airway constriction. Furthermore, beta2 agonism functionally suppresses the cellular degranulation of mast cells and basophils, which limits the subsequent release of inflammatory mediators like histamine. This action modulates activity in the respiratory and inflammatory pathways, resulting in a reduction of airway resistance.

How to Use Emerade

The administration of Emerade follows a specific protocol, emphasizing immediate action and a precise delivery route for the emergency treatment of severe acute allergic reactions.

Administration Scope

Entity	Instruction
Route of administration	Intramuscular (IM) injection only, into the outer side of the thigh (anterolateral aspect).
Dosing schedule	Adults/Adolescents (>30 kg): Initial dose is 300 micrograms, potentially increasing to 500 micrograms for individuals over 60 kg based on assessment.
	Children (15 kg to 30 kg): The established initial dose is 150 micrograms.
Age-group rules	Children below 15 kg: Use is not recommended due to potential dosing inaccuracy, unless medical advice dictates otherwise in a life-threatening situation.

---

Frequency and Procedural Structure

The usage pattern is strictly for acute intervention and not for scheduled or long-term management.

Classification	Principle
Frequency pattern	As-needed (PRN), for a single, acute event.
Re-dosing Window	A second dose may be administered 5 to 15 minutes after the first, only if the symptoms persist or worsen.
Special procedural conditions	The injection site should be massaged for 10 seconds following injection to accelerate absorption.
Post-administration action	Urgent professional medical assistance must be sought immediately following administration, regardless of the patient's initial response.

---

Connection to the Overall Use Protocol

The use of Emerade is an acute, short-term emergency intervention defined by precise, weight-based intramuscular dosing. The protocol mandates immediate administration followed by a strict 5-to-15 minute re-dosing interval and a requirement to urgently seek medical care, establishing the auto-injector as the critical first step in an urgent medical chain of events, not the final treatment.

Recent Clinical Evidence and Safety Information

Clinical studies involving adrenaline auto-injectors (AAIs) typically focus on pharmacokinetics (how the drug is absorbed and used by the body) and device performance. Emerade (adrenaline) is an auto-injector intended for the emergency treatment of severe allergic reactions (anaphylaxis).

---

Pharmacokinetic Studies

Research has explored the rate of adrenaline absorption, aiming for rapid delivery into the muscle (intramuscular, IM) to counteract the effects of anaphylaxis quickly. Studies have investigated differences in the time to peak plasma adrenaline concentration ( Tmax) and the maximum concentration ( Cmax) between various AAI brands and needle lengths. Results suggested that the longer needle lengths used in the Emerade design may increase the likelihood of IM delivery in a greater proportion of patients compared to devices with shorter needles, which is associated with a faster drug effect.

Specific studies comparing Emerade 500mu g to other 300mu g devices have provided data on the resulting plasma epinephrine profiles, supporting the potential for a higher dose in adults over 60 kg as recommended by some professional guidelines.

---

Device Performance and Regulatory Actions

Recent regulatory actions have centered on the mechanical reliability of the Emerade device. Due to reports of potential failure to activate or premature activation, particularly after the device was dropped or subjected to stress, the Medicines and Healthcare products Regulatory Agency (MHRA) and other health authorities initiated recalls of all Emerade strengths (150mu g, 300mu g, and 500mu g).

Regulatory advisories have focused on the following:**

Issue Type	Observed Risk in Testing
Activation Failure	Failure to deliver the adrenaline dose when activated.
Premature Activation	Adrenaline released before administration, often after dropping the pen.

These safety alerts prompted healthcare professionals to prescribe alternative AAI brands (such as EpiPen or Jext) to patients until the device's technical issues could be resolved by the manufacturer. Current clinical guidance emphasizes that patients should always carry two adrenaline auto-injectors.

Key Studies & References

1. National Patient Safety Alert: Recall of Emerade 500 micrograms and Emerade 300 micrograms auto-injectors, due to the potential for device failure (NatPSA/2023/004/MHRA)
2. Pharmacokinetic and pharmacodynamic evidence of adrenaline administered via auto-injector for anaphylactic reactions: A review (Discussion of optimal dose and needle length)

Common questions about Emerade (FAQ)

Q: Is Emerade the same type of medication as an EpiPen?

A: The active substance in Emerade is adrenaline (epinephrine), which is the medication used in similar auto-injectors for the emergency treatment of anaphylaxis. Regulatory documents confirm this active ingredient is a non-selective adrenergic agonist.

Q: How quickly is Emerade expected to work after administration?

A: Official information indicates that the injection into the muscle (intramuscular) is associated with rapid absorption. Studies have shown that the peak concentration of adrenaline in the bloodstream is generally reached in about 8 minutes following an intramuscular injection.

Q: How long does the effect of Emerade usually last?

A: The effect of the medication is short-acting. Because the drug's effect is temporary, official protocol emphasizes seeking urgent medical assistance immediately after administration and allows for a second dose after 5 to 15 minutes if symptoms persist or worsen.

Q: Does using Emerade cause any immediate noticeable feelings or symptoms?

A: Yes, the body's response to the medication is rapid and can cause immediate feelings. Common effects noted in product information can include feelings of anxiety, restlessness, shakiness, paleness, and a fast or pounding heartbeat (tachycardia).

Q: Can Emerade be used for allergic reactions that are not anaphylaxis?

A: Regulatory documents state that the product is indicated strictly for the emergency treatment of severe acute allergic reactions (anaphylaxis). Official product information states the drug is for the emergency treatment of severe reactions and does not describe its use for non-severe allergic reactions.

Q: Can Emerade interact with common over-the-counter medicines?

A: Yes, interactions are documented with certain drug classes. For example, regulatory-linked information on adrenaline suggests that some ingredients found in common non-prescription medicines, like certain cold preparations, may interact.

Q: Are there specific health conditions that make using Emerade difficult or risky?

A: Official documents advise using the product with caution in patients with certain pre-existing conditions. Conditions requiring caution include heart diseases (such as angina or arrhythmia), hypertension (high blood pressure), hyperthyroidism, and diabetes. The official documents emphasize that the life-saving nature of the drug may override these concerns in an emergency.

Q: Is Emerade effective against all types of severe allergy triggers?

A: The official product information indicates that the pen is for anaphylaxis triggered by a wide range of allergens, including foods, medicines, insect stings or bites, and other allergens. It is also indicated for severe allergic reactions that are exercise-induced or where the cause is idiopathic (unknown).

Q: Can Emerade be exposed to extreme temperatures, like freezing or intense heat?

A: Official regulatory alerts advise that the pens must be stored within a specific temperature range, generally below 25 C, and away from heat. Exposure to extreme temperatures may negatively affect device function.

Q: Do pregnant or breastfeeding individuals need special advice about Emerade?

A: Regulatory documents indicate that use in pregnancy requires caution. However, it is generally considered the necessary first-line treatment for anaphylaxis, meaning the risk of delaying treatment is greater than the risk from the medicine itself. Regulatory documents also indicate that the small amount of adrenaline passed into breast milk is unlikely to affect a nursing infant.

Q: What if the auto-injector is accidentally pressed, is that dangerous?

A: Yes, accidental injection, particularly into areas like the hand or finger, is known to be dangerous. The regulatory documents warn that this can cause peripheral ischaemia (restriction of blood flow). In this event, immediate emergency medical attention is necessary.

Q: How is the long-term safety of Emerade monitored by health authorities?

A: Health authorities continuously monitor the safety of the product after it is released to the market. This includes investigating reports of device malfunction and issuing regulatory actions, such as product recalls, when specific safety risks are identified.

Q: Are there any reported differences in performance between the different Emerade doses?

A: Clinical studies indicate differences in the resulting concentration of adrenaline in the blood. The higher 500mu g dose resulted in a higher peak concentration compared to the 300mu g dose, supporting its recommended use in larger adult patients.

Q: What are the most serious side effects listed in the official documents for Emerade?

A: Although severe side effects are rare, serious events noted in product information can include irregular heartbeat (arrhythmia), chest pain (angina pectoris), severe skin infection at the injection site, and symptoms similar to a stroke.

Q: Do any common foods or supplements interact with Emerade?

A: Official product information on the active ingredient adrenaline indicates a moderate interaction risk with caffeine. This means that consuming caffeine, found in common beverages and supplements, could potentially enhance effects like increased heart rate and blood pressure after administration.

Q: What are the official recommendations regarding storing Emerade?

A: Official documents advise storing the pen away from heat and generally below 25 C to protect the integrity and function of the auto-injector device.

Q: Is there a shelf life or expiration date I should watch out for on Emerade?

A: Yes, like all medicines, the auto-injector has an expiration date. Patients are officially reminded to regularly check the pen’s expiration date. Checking that the pen is not past its use by or expiry date helps ensure the medication remains effective when needed.

Q: What should be done if the Emerade injector looks damaged or expired?

A: Health authorities advise that if the pen is damaged or expired, it should be replaced immediately. The damaged or expired pen should be returned to a pharmacy after a new device has been obtained.

Q: Does Emerade contain any common allergens itself?

A: The product contains the excipient sodium metabisulphite, which is noted in regulatory documents. This substance is known to potentially cause allergic reactions, including bronchospasm (narrowing of airways), particularly in individuals with a history of asthma.

Q: Is Emerade suitable for individuals with certain heart conditions?

A: While the medicine is life-saving, official documents state it should be used with caution in patients with pre-existing heart diseases. The patient is generally reminded to inform emergency medical staff of their underlying condition.

Q: What is the official guidance on who should not use Emerade?

A: Regulatory documents state that there are no absolute contraindications for its use in an allergic emergency, given its life-sustaining role. However, regulatory documents indicate that use is not recommended for children weighing less than 15 kg due to the risk of inaccurate dosing, unless otherwise advised by a healthcare professional in a life-threatening situation.

Q: Are there different forms of the medication other than the auto-injector?

A: The approved product is a pre-filled auto-injector pen. However, in professional healthcare settings, official guidance sometimes advises using adrenaline from ampoules with a syringe and needle.

Q: What does 'contraindications' mean in relation to Emerade?

A: A contraindication generally means a medical reason to avoid a drug. For Emerade, regulatory documents state there are no absolute contraindications because its life-sustaining emergency purpose overrides most potential health risks.

Q: Can I use Emerade if I have a severe asthma attack without an allergic trigger?

A: The official product information indicates the drug is for the emergency treatment of severe acute allergic reactions (anaphylaxis). Regulatory documents do not describe the use of the product for asthma attacks without an allergic trigger.

Q: Is the medication inside Emerade similar to adrenaline naturally produced by the body?

A: Yes, the active medication, epinephrine (adrenaline), belongs to a class of medicines called sympathomimetics. These agents chemically resemble the hormones the body naturally produces and releases during stress or emergencies.

Q: What evidence exists about the drug's effectiveness in real-world scenarios?

A: While most studies focus on absorption and device function, official patient warnings discuss the risk of biphasic anaphylaxis (symptoms returning hours later). This shows an awareness of real-world patient complexity beyond the initial effect of the dose.

Q: What is meant by the phrase 'life-saving medicine' when describing Emerade?

A: It is described as a life-sustaining treatment in an emergency because it is designed to temporarily counteract the life-threatening effects of anaphylaxis, such as a severe drop in blood pressure and airway swelling, while the patient awaits definitive medical care.

Q: How are the side effects of Emerade generally managed?

A: Regulatory-linked patient resources suggest that for side effects that are severe or bothersome, individuals are generally advised to consult their doctor or pharmacist for advice on management.

Q: Are there special considerations for using Emerade in older adults?

A: Yes, official documents note that there is a risk for adverse reactions after administration of adrenaline in elderly patients. Therefore, the drug should be used with caution in this age group.

Q: What are the known risks of accidental injection into the hand or finger?

A: The primary known risk is peripheral ischaemia (restricted blood flow), which can be caused by accidental injection into the hand or finger. Official guidance specifies that this requires immediate hospital attention.

Q: What are the symptoms or reactions that Emerade is intended to stop or reduce?

A: The drug is intended to stop or reduce life-threatening symptoms of anaphylaxis, such as dangerously low blood pressure, difficulty breathing, swelling of the face and throat, as well as other signs like hives, fast heart rate, and dizziness.

Storage and Disposal Requirements

Scope Element	Official Regulatory Requirement
Storage Temperature	Store at room temperature, specifically 20 C to 25 C.
Prohibited Environments	Do not freeze or refrigerate; protect from light and avoid extreme heat or cold.
Packaging	Keep in the original outer carton and the manufacturer-provided carrying case.
Stability Check	Must be discarded and replaced if the solution is discolored, contains particles, or if the pen is suspected of damage after being dropped.
Child Protection	Keep out of the sight and reach of children.
Disposal Instructions	Dispose of unused or expired product according to local regulations.

Official Storage and Disposal Summary

The regulatory label mandates storing the Emerade auto-injector within a controlled room temperature range and strictly prohibits refrigeration or freezing. The pen must be kept protected from light in its original packaging. Replacement is required if the solution shows visual changes, the device is damaged, or the expiration date has passed. Unused medication must be kept out of the reach of children, and disposal must follow local regulations intended to help protect the environment.